{"id":"a-101-topical-solution","_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=A-101 Topical Solution","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T05:05:53.781796+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T05:05:59.630139+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=A-101 Topical Solution","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T05:05:59.969380+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108694/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:06:01.161326+00:00"}},"_dailymed":null,"_scrapedAt":"2026-03-28T00:26:01.966Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T05:06:02.942868+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT02260180","phase":"PHASE2","title":"Study of A-101 for the Treatment of Seborrheic Keratosis","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2014-10","conditions":"Seborrheic Keratosis","enrollment":119},{"nctId":"NCT03812510","phase":"PHASE3","title":"Safety Study of A-101 Topical Solution for the Treatment of Common Warts","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2019-02-07","conditions":"Common Wart","enrollment":426},{"nctId":"NCT03691831","phase":"PHASE3","title":"A Study of A-101 Topical Solution for the Treatment of Common Warts","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2018-09-13","conditions":"Common Wart","enrollment":502},{"nctId":"NCT03687372","phase":"PHASE3","title":"Study of A-101 Topical Solution for the Treatment of Common Warts","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2018-09-17","conditions":"Common Wart","enrollment":503},{"nctId":"NCT03224598","phase":"PHASE2","title":"A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2017-06-26","conditions":"Dermatosis Papulosa Nigra","enrollment":39},{"nctId":"NCT03487588","phase":"PHASE4","title":"An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2018-03-21","conditions":"Seborrheic Keratosis","enrollment":41},{"nctId":"NCT03148691","phase":"PHASE2","title":"A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2017-05-17","conditions":"Seborrheic Keratosis","enrollment":253},{"nctId":"NCT03210337","phase":"PHASE2","title":"A Phase2 of A-101 Topical Solution in Subjects With Common Warts","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2017-08-01","conditions":"Common Wart","enrollment":157},{"nctId":"NCT03278028","phase":"PHASE2","title":"A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2017-07-13","conditions":"Common Wart","enrollment":159},{"nctId":"NCT02160626","phase":"PHASE2","title":"Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2014-06","conditions":"Seborrheic Keratosis","enrollment":172},{"nctId":"NCT01986920","phase":"PHASE1, PHASE2","title":"Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2013-10-22","conditions":"Seborrheic Keratosis (SK)","enrollment":35},{"nctId":"NCT02669862","phase":"PHASE2","title":"A Study of A-101 Solution in Subjects With Common Warts.","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2015-12-21","conditions":"Common Warts","enrollment":98},{"nctId":"NCT02667288","phase":"PHASE3","title":"An Open-Label Safety Study of A-101 Solution","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2016-01","conditions":"Seborrheic Keratosis","enrollment":147},{"nctId":"NCT02667275","phase":"PHASE3","title":"A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2016-01","conditions":"Seborrheic Keratosis","enrollment":487},{"nctId":"NCT02667236","phase":"PHASE3","title":"A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2016-01","conditions":"Seborrheic Keratosis","enrollment":450}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL2108694"},"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"A-101 Topical Solution","genericName":"A-101 Topical Solution","companyName":"Aclaris Therapeutics, Inc.","companyId":"aclaris-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":3,"withResults":3},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T05:06:02.942868+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}